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Abstract
Background: Previous studies have demonstrated that regulatory T cells (Tregs) play a protective role in the
pathogenesis of chronic graft-versus-host disease (cGVHD). Tregs constitutively express the gene of the transcription
factor Foxp3 whose CNS2 region is heavily methylated in conventional CD4+ T cells (CD4+Tconvs) but demethylated
in Tregs.
Methods: Here, we assessed the impact of azacytidine (AZA) on cGVHD in a well-established murine model of
sclerodermic cGVHD (B10.D2 (H-2d)→ BALB/cJ (H-2d)).
Results: The administration of AZA every 48 h from day +10 to day +30 at the dose of 0.5 mg/kg or 2 mg/kg
mitigated chronic GVHD. Further, AZA-treated mice exhibited higher blood and thymic Treg frequencies on day +35, as
well as higher demethylation levels of the Foxp3 enhancer and the IL-2 promoter in splenocytes at day +52. Interestingly,
Tregs from AZA-treated mice expressed more frequently the activation marker CD103 on day +52. AZA-treated mice had
also lower counts of CD4+Tconvs and CD8+ T cells from day +21 to day +35 after transplantation, as well as a
lower proportion of CD4+Tconvs expressing the Ki67 antigen on day +21 demonstrating an anti-proliferating
effect of the drug on T cells.
Conclusions: Our results indicate that AZA prevented sclerodermic cGVHD in a well-established murine model
of cGVHD. These data might serve as the basis for a pilot study of AZA administration for cGVHD prevention in
patients at high risk for cGVHD.
Keywords: AZA, Azacytidine, Decitabine, DAC, Treg, Regulatory T cells, GVHD, Graft-versus-host disease, Chronic
graft-versus-host disease, Sclerodermic graft-versus-host disease
Background
Despite its association with graft-versus-tumor effects
[1–6], chronic graft-versus-host disease (cGVHD) re-
mains an important limitation of allogeneic hematopoietic
cell transplantation (allo-HCT) [7–9]. CGVHD manifesta-
tions can be remarkably polymorphic, ranging from iso-
lated lichenoid cunatenous and/or oral mucosa lesions
to dramatic multi-systemic disease mimicking severe
forms of systemic lupus erythematosus or systemic
sclerosis [8, 10].
Recent progresses have been made in our under-
standing of cGVHD pathogenesis [10, 11]. It is now
well-demonstrated that clinical manifestations of cGVHD
in humans are mediated by a complex immune reaction
involving donor conventional CD4+ and CD8+ T cells,
regulatory T cells (Tregs), B cells, and regulatory B cells
[10, 12, 13]. However, the beneficial effect of in vitro [14,
15] or in vivo [6, 16–18] T-cell depletion of the graft at
preventing cGVHD demonstrates a primary role for donor
T cells in cGVHD pathogenesis.
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Regulatory T cells (Tregs) represent a fraction of CD4+ T
cells that is indispensable for maintaining immunological
self-tolerance [19, 20]. Tregs constitutively express the fork-
head box protein 3 factor (Foxp3) in their nuclei, and CD25
(the high-affinity component of the trimeric form of the
interleukin 2 (IL-2) receptor) on their cell surface [19, 20].
Consequently, IL-2 is the key cytokine for Treg homeosta-
sis [20, 21]. Interestingly, an altered Treg homeostasis has
been observed in patients with cGVHD [22–25], while
transfer of activated (CD103+) Tregs ameliorated cGVHD
in a mouse-to-mouse model of cGVHD [26]. Further, re-
markably, correction of Treg homeostasis by administration
of low-doses of IL-2 induced clinical responses in approxi-
mately 50 % of patients suffering from steroid-refractory
cGVHD [23].
Although forced expression of Foxp3 in conventional
CD4+ T cells (CD4+Tconvs) confers them a suppressive
activity [27], Foxp3 expression per se is not sufficient for
stably maintaining Treg phenotype and suppressive func-
tions [28]. Indeed, Treg-specific epigenetic changes (such
as DNA hypomethylation) are also involved in controlling
the expression of some Tregs function-associated mole-
cules such as IL-2ra, CTLA4, or Foxp3 itself [28]. Among
these epigenetic changes, Foxp3 conserved noncoding se-
quence 2 (CNS2) is unmethylated in Tregs while heavily
methylated in CD4+Tconvs, and greatly contributes to the
stability of Foxp3 expression as well as Treg phenotype
and functions [28]. Further, the Foxp3 enhancer is also
demethylated in Tregs while heavily methylated in
CD4+Tconvs [29]. Previous studies have demonstrated
that hypomethylating agents (HMA) such as azacytidine
(AZA) or decitabine (DAC) induce Foxp3 expression both
in vitro and in vivo [30, 31] through the demethylation of
Foxp3 CNS2 region [30] and Foxp3 enhancer [29].
Based on these findings, we herein investigated the
impact of AZA on sclerodermic cGVHD (scl-cGVHD)
in a classical murine model of scl-cGVHD (B10.D2
(H-2d)→ BALB/cJ (H-2d)) [32–35].
Methods
Mice and drugs
Twelve- to 14-week-old B10.D2 (H-2d, Jackson Labora-
tories, Bar Harbor, USA) and BALB/cJ (H-2d, Jackson
Laboratories) mice were used as donors and recipients,
respectively. All mice were maintained in top-filtered
cages in a standard animal facility and provided with
sterilized food. Sterilized water, supplemented with 1 %
Baytril (Bayer HealthCare, Diegem, Belgium), was given
from day 0 to the end of the experiment. Water was
changed every 2–3 days. All experimental procedures
and protocols used in this investigation were reviewed
and approved by the Institutional Animal Care and Use
Ethics Committee of the University of Liège (Belgium),
reference 1438. The “Guide for the Care and Use of
Laboratory Animals”, prepared by the Institute of La-
boratory Animal Resources, National Research Council,
and published by the National Academy Press, was
followed carefully as well as European and local legis-
lation. 5-Azacytidine (AZA, Sigma-Aldrich, St. Louis,
MO) or Decitabine (DAC, Dacogen, Janssen-Cilag,
Zug, Switzerland), solubilized in PBS (Lonza, Verviers,
Belgium), were injected s.c. every 48 h from D + 10 to
D + 30 at the dose of 0.5 mg/kg or 2 mg/kg for AZA
and 0.75 mg/kg for DAC. Control mice did not receive
any injection.
Cell preparation for bone marrow transplantation
Spleen, femurs and tibias from B10.D2 (or from BALB/
cJ in case of syngeneic transplantation) mice were col-
lected in sterile RPMI + 10 % FBS + 1 % penicillin/
streptomycin. After red blood cell lysis (RBC lysis buffer;
eBioscience, SD, USA), suspensions were passed through
a 70 μm nylon filter mesh and washed with PBS + 3 %
FBS + 1 % P/S. Cells were then resuspended and mixed
in PBS at a concentration of 70 × 106 spleen cells and
10 × 106 bone marrow cells/200 μL and injected intra-
venously in recipient mice.
Bone marrow transplantation and scl-cGVHD
BALB/cJ recipient mice were transplanted as previously
described by Jaffee and Claman [32]. Briefly, recipients
BALB/cJ mice (H-2d) first received a total body irradi-
ation of 7 Gy (137Cs source, GammaCell 40, Nordion,
Ontario, Canada). Five to six hours later, recipients were
injected with 200 μL of the above described cell suspen-
sion. The severity of sclerodermatous cGVHD (scl-
cGVHD) was assessed with a clinical scoring system as
described earlier [35]. Briefly, ear-tagged animals were
individually scored three times/week for five parameters:
weight loss (grade 1, 10–20 %; grade 2, >20 %), posture
(1, kyphosis only at rest; 2, severe kyphosis when the
animal moves), activity (1, moderate activity impairment;
2, no move unless stimulated), skin (1, erythema or scal-
ing tail; 2, open lesion on the body surface), and hair loss
(1, > 1 cm2; 2, > 2 cm2). Clinical score was generated by
summation of the five criteria scores (0–10/10). Animals
reaching a score of 8/10 or a weight loss of >20 % of ini-
tial weight were sacrificed to avoid unnecessary pain ac-
cording to our local ethic committee recommendations.
Mice were observed every day for general health during
the whole course of the experiments.
After 52 days, mice were sacrificed by anesthesia with
2 % Isoflurane (Forene®, Abbott Laboratories, Chicago,
Illinois, USA) followed by cervical dislocation. Con-
firmation of death was done by monitoring absence of
heart contraction or respiratory movements for 15 min.
Splenocytes and bone marrow cells were collected in
sterile RPMI + 10 % FBS + 1 % P/S. Lungs and skin were
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harvested in 10 % formaldehyde while blood and serum
were collected in K2EDTA tubes and SST tubes, respect-
ively (Becton Dickinson, Franklin Lakes, New Jersey, USA).
Skin, lungs and thymus biopsies and
immunohistochemistry
On day +29 after transplantation (two first cohorts of
mice) or at sacrifice (day +52, third cohort of mice) skin
samples of 0.5 cm2 from the upper back were obtained
and directly fixed in 10 % formaldehyde for 48 h, em-
bedded in paraffin and sectioned at 4–5 μm. Similarly,
lungs (third cohort at day +52) and thymus (fifth cohort
on day +35) were collected at sacrifice and directly fixed
in 10 % formaldehyde for 48 h, embedded in paraffin and
sectioned at 4–5 μm. Skin and lung sections were then
stained with Goldner’s trichrome using Masson-Goldner
staining kit following the manufacturer’s instructions
(Merck Millipore, Darmstadt, Germany). Pulmonary fibro-
sis was assessed using the Ashcroft’s scale [36]. Thymic
sections were stained with hematoxylin-eosin. For CD11b
staining, paraffin-embedded sections were deparaffinized
in xylene and rehydrated through a graded ethanol series.
Antigen was retrieved with EDTA buffer combined with
heating in a pressure cooker. Slides were peroxidase
blocked with a commercial protein block serum-free solu-
tion (Dako, Glostrup, Danemark) for 10 min and were
then incubated with the CD11b antibody (Abcam PLC,
Cambridge, UK) during 1 h at room temperature and
detected with the Envision system (Dako) for 30 min.
Colorimetric detection was completed with diamino-
benzidine (Dako) and slides were then counterstained
with hematoxylin. Slides were then examined by a blinded
examinator (JS) using a scoring system consisting in an
absolute count of CD11b+ cells in three different hotspots,
defined as areas in which CD11b staining is particularly
high, for each slide. The total number of positive cells was
then normalized to the number of CD11b+ cells per mm2.
Histological slides were then scanned with a Hamamatsu
Nanozoomer 2.0 HT (Hamamatsu Photonics, Geldern,
Germany).
Blood counts and flow cytometry
Blood was collected immediately after tail vein bleeding
in BD Microtainer K2EDTA Tube (BD Biosciences, SD,
USA). Splenocytes were obtained by crushing the spleen
in RPMI 1640 + 10 % FBS. Blood cell populations were
counted with a cell-dyn 3700 analyzer (Abbott Laborator-
ies, Chicago, Illinois, USA). Erythrocytes were depleted
using RBC lysis buffer (eBioscience) according to manu-
facturer’s instructions. Cells were washed in PBS + 3 %
FBS (Lonza) before processing for flow cytometry. The fol-
lowing antibodies were used: anti-mouse CD3-V500
(500A2, Becton-Dickinson, Bedford, MA), anti-mouse
CD3-PE (500A2), anti-mouse CD4-eFluor450 (RM4-5),
anti-mouse CD4-APC-Cy7 (RM4-5, SONY Biotechnology,
Weybridge, UK), anti-mouse CD8-PE-Cy7 (53–6.7), anti-
mouse CD8-APC-eFluor780 (53–6.7), anti-mouse CD229.1-
FITC (30C7, BD), anti-mouse CD25-APC (PC61.5),
anti-mouse CD25-PE-Cy7 (PC61, BD), anti-mouse
CD25-PercP-Cy5.5 (PC61.5), anti-mouse CD103-BV510
(M290, BD), anti-mouse CD90.2 APC (53–2.1) (all
eBioscience unless indicated otherwise). Cells (1.5–2 × 106
cells/sample) were incubated with surface antibodies for
20 min at 4 °C in the dark and washed twice with PBS + 3 %
FBS. Intracellular staining for Foxp3 and Ki67 was
performed by using the FoxP3 staining buffer set
(eBioscience). For pSTAT5 staining, the PerFix EXPOSE
reagent kit (Beckman Coulter, Fullerton, CA) was used
following the manufacturer’s instruction as previously
reported [37]. The following antibodies were used:
anti-mouse Foxp3-APC (FJK-16 s, eBioscience), anti-
mouse Foxp3-PE (FJK-16 s, eBioscience), anti-human
phophoSTAT5-APC (pY694, BD) and anti-human
Ki67-FITC (35/Ki-67, BD). Data were acquired on a FACS
Canto II flow cytometer (Becton Dickinson) and analyzed
with the FlowJo software 10.0.7 (Tree Star Inc., Ashland,
OR). Cell phenotypes were defined as CD3+CD8+ for cyto-
toxic CD8+ T cells, CD3+CD4+Foxp3- for CD4+Tconvs
and CD3+CD4+Foxp3+ for Tregs. In the thymus, popula-
tions were described as follow: CD90.2+CD4-CD8- for
double negative (DN), CD90.2+CD4+CD8+ for double
positive (DP), CD90.2+CD4+CD8- for single CD4 positive,
CD90.2+CD4-CD8+ for single CD8 positive, and
CD90.2+CD4+CD8-Foxp3+ for Tregs. Absolute counts
were calculated by multiplying the percentage of positive
cells in the lymphoid gate by the absolute lymphocyte
count measured by the cell-dyn 3700 analyzer, as previ-
ously reported [38].
For qPCR assays, Tregs and CD4+Tconvs were sorted
from spleen of unmanipulated B10.D2 mice using FACS
Aria III (Becton Dickinson).
Methylation-sensitive restriction enzyme and qPCR
(MSRE-qPCR)
Methyl-sensitive PCR were used to analyze the methyla-
tion status of the CpG island of the Foxp3 enhancer and
the IL-2 promoter, as previously described [29, 39, 40].
Genomic DNA was prepared using PureLinkTM Genomic
DNA Mini Kit (Invitrogen, CA, USA) and quantified. One
hundred and fifty nanograms of genomic DNA isolated
from murine splenocytes was digested overnight at 37 °C
with 10U of HpaII or MspI enzymes for Foxp3 enhancer
and with 10U of PleI or MlyI enzymes for IL-2 promoter
analyses. The CpG islands and β-act genes were PCR amp-
lified using the following specific primers: Foxp3 enhancer
CpG island, 5′-ATCCTCGCCATCGTCTTCCTCAT-3′
(forward) and 5′-CCTGTTCTGGCTTTCTCATTGGCT-
3′ (reverse); IL-2 CpG island, 5′- CTGTTTCCATGCTGA
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AGGTC-3′(forward) and 5′-GGGTGATGCTCCAACTT
CAT-3′ (reverse); β-act (GenBank accession no. U89400),
5′-TAGCACCATGAAGATCAAG-3′ (forward) and 5′-CC
TGCTTGCTGATCCACAT-3′ (reverse). Specific primers
designed on CpG islands were selected according to the
CpG island methylation tool server (http://urogene.org/
methprimer). Quantitative real-time PCR was performed
using the LightCycler 480 thermocycler and the KAPA
SYBR FAST qPCR kit, following the manufacturer’s in-
structions (Kapa Biosystems, Wilmington, USA,), subse-
quently the melting curve analysis was performed. Data
were normalized using the β-act Endogenous Control and
β-act specific primer for uncut region by HpaII, MspI, PleI
and MlyI. Differences between males and females were
taken into account for Foxp3 analyses, since this gene gene
is located on the X chromosome.
TCR Vβ CDR3-size spectratype analysis
The TCR Vβ CDR3-size spectratyping was performed as
previously reported [35] (see supplemental data for more
details).
Statistical analyses
The Mann-Whitney U test was used to compare data
between experimental groups. Results are expressed as
mean with SEM (for scl-GVHD scores), or median, 25th
and 75th percentiles of the distribution (boxes), and
whiskers extending to the 5th and 95th percentiles. The
analysis of quantitative real time PCR data was based on
2−ΔΔCT values. Two-tailed P values <0.05 were consid-
ered as statistically significant. Statistical analyses were
performed with the GraphPad Prism 5.0 software.
Results
AZA mitigates scl-cGVHD
In a first set of two consecutive experiments, Balb/cJ
mice were injected i.v. with 10.106 bone marrow cells
and 70.106 splenocytes from B10.D2 donor mice after le-
thal irradiation. Mice were then given (or not) azacytidine
(AZA) administered subcutaneously every 48 h from
day +10 to day +30. We observed that AZA, at either
0.5 or 2 mg/kg doses, significantly mitigated cGVHD
with mice from the AZA group having significantly
lower cGVHD scores than control mice from day +35
to the end of the experiment (day +52) (Fig. 1a). In ac-
cordance with the similar cGVHD scores between the
two groups of mice on day +29 after transplantation,
skin fibrosis (assessed by trichrome staining) was simi-
lar in AZA and control mice at that time point (data
not shown).
In a third experiment, we confirmed that AZA given
at 2 mg/kg decreased cGVHD (Fig. 1b) and observed
that decitabine (DAC, 0.75 mg/kg, n = 5) also mitigated
cGVHD (Additional File 1: figure S1). We further evaluated
skin fibrosis in the mice at the end of the experiment.
As shown in Fig. 2, AZA-treated mice had higher total
thickness (from epidermis to sub-cutaneous muscle
layer)/collagen thickness (TT/CT) ratios, highlighting
less skin fibrosis (Fig. 2a, b), but similar (and mild) lung
fibrosis (Fig. 2c, d) than control mice on day 52 after
transplantation. Interestingly, infiltration by monocytes/
macrophages was similar in AZA and control mice on that
day (Fig. 2e, f ).
In a fourth experiment, we investigated whether AZA
administered every 4 days from days 10 to 30 also pre-
vented cGVHD. As shown in Additional File 1: figure S1,
this was not the case, with AZA and control mice exhibit-
ing similar cGVHD scores throughout the experiment.
Impact of AZA on blood cell counts and immune recovery
We next assessed the impact of AZA on blood cell counts
and immune recovery in the first two experiments. We
observed that AZA significantly decreased total white
blood cell (Fig. 3a) and lymphocyte (Fig. 3b) counts on
days +21 and +35 after transplantation, while hemoglobin
levels remained comparable in both groups (Fig. 3c). Fur-
ther, AZA significantly decreased absolute counts of both
CD4+Tconvs (Fig. 3d) and CD8+ T cells (Fig. 3e) from
day +21 to day +35 after transplantation. In contrast,
there was a trend for higher absolute lymphocyte counts
in AZA-treated mice on day +52. This was due to signifi-
cantly higher numbers of CD3- lymphocytes (probably
mainly B cells) in AZA-treated mice (P = 0.01), as ob-
served previously by Choi et al. in a mouse-to-mouse
model of acute GVHD [31]. This is probably an indirect
phenomenon (better B lymphopoiesis due to less intense
cGVHD in AZA-treated mice) since this was not observed
in mice given syngeneic transplantation (Additional File 1:
figure S2).
Interestingly, the proportion of proliferative CD4+Tconvs
and CD8+ T cells (as assessed by Ki67 expression) was
lower in AZA-treated mice on day +21 after transplantation
(Fig. 3f, g) (this effect was dose dependent since it was only
observed in mice given 2 mg/kg of AZA), suggesting an
anti-proliferating effect of AZA on T cells. However, upon
AZA discontinuation, CD4+Tconvs and CD8+ T cells prolif-
eration was restored and higher numbers of Ki67+ cells
were observed in AZA treated mice at days +35 and +49
post-transplant. Comparable qualitative observations were
made on day 35 with DAC in the third experiment
(Additional File 1: figure S3).
AZA increases Treg frequency and induces demethylation
of Foxp3 enhancer
Given that AZA induces Tregs in vitro, we assessed the
impact of HMA on Treg reconstitution. In the two first
experiments, we observed that AZA increased the fre-
quency of Tregs (Fig. 4a) and decreased the CD4+Tconv/
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Treg ratio (P = 0.046 for mice treated with AZA 0.5 mg/
Kg and P = 0.029 for mice treated with AZA 2 mg/kg)
on day +35 after transplantation. In contrast, absolute
counts of Tregs were significantly lower in AZA-treated
mice on days +21 and +35 after transplantation (data
not shown). Comparable findings were observed in the
third experiment with AZA 2 mg/kg (Fig. 4b) and DAC
(Additional File 1: figure S3). Further, interestingly, Tregs
from the spleens of AZA- and DAC-treated mice
expressed more frequently the activation marker CD103
than those from control mice on day +52 after transplant-
ation, suggesting higher efficacy (Fig. 4c and Additional
File 1: figure S3). A similar impact of AZA on Tregs was
observed in mice given syngeneic grafts (Additional File 1:
Fig. 1 Azacytidine mitigates scl-cGVHD. Balb/cJ mice were injected i.v. with 10.106 bone marrow cells and 70.106 splenocytes from B10.D2 donor
mice (or from Balb/cJ mice in case of syngeneic transplantation) after lethal irradiation. Mice were then given (or not) azacytidine (AZA) administered
subcutaneously every 48 h from day +10 to day +30. Animals were individually scored three times/week and animals reaching a score of 8/10 were
sacrificed (evolutions of the number of animals along the course of each experiment are shown under each graph). a Pooled GVHD scoring of two
independent groups (two distinct experiments) of mice given or not AZA (0.5 or 2 mg/kg) showing lower GVHD scores in AZA-treated mice. Two out
of 15 control mice died during the experiments due to achievement of the critical score of 8/10 and three others because of weight loss >20 %.
Concerning mice receiving AZA 0,5 mg/kg, three out of 14 mice were sacrificed during the experiment because a weight loss >20 % and 1 due to
achievement of the critical score. For mice treated with AZA 2 mg/kg, two mice were sacrificed because of a weight loss >20 % and two did not
survive the anesthesia administered for skin biopsy performed during the experiment (day +29). b GVHD scoring of a third cohort of mice given or
not AZA (2 mg/kg only) confirming lower GVHD scores in treated mice. Three out of eight control mice were sacrificed because they achieved the
critical score of 8/10, while all AZA mice survived without achieving the critical GVHD score. Results are expressed as mean with SEM. *P < 0.05;
**P < 0.01; ***P < 0.001
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figure S4), demonstrating that the impact of AZA on Treg
reconstitution was independent of cGVHD.
Previous studies have reported that CD8+Foxp3+
regulatory T cells expanded after experimental allogen-
eic bone marrow transplantation in mice and mitigated
experimental acute GVHD [41, 42]. This led us to look
whether AZA promoted the generation of CD8+Foxp3+
regulatory T cells in vivo. However, we failed to ob-
serve significant numbers of CD8+Foxp3+ regulatory T
cells in control and in AZA-treated mice after either
allogeneic or syngeneic transplantation (Additional File 1:
figure S5).
The higher frequency of Tregs in AZA-treated mice
on day +35 prompted us to assess the impact of AZA on
the methylation status of the Foxp3 enhancer. We first
quantified the methylation status of Foxp3 enhancer in
CD4+ Tconvs and Tregs isolated from the spleen of
healthy mice. For this, DNA was extracted and digested
with two restriction enzymes, Hpall and Mspl, both
recognizing CG sequences. It is worth to note, however,
Fig. 2 Azacytidine mitigates skin fibrosis on day +52. Balb/cJ mice were injected i.v. with 10.106 bone marrow cells and 70.106 splenocytes from
B10.D2 donor mice after lethal irradiation. Mice were then given (or not) azacytidine (AZA, 2 mg/kg) administered subcutaneously every 48 h
from day +10 to day +30. At sacrifice (day +52), histology was performed on lung and skin samples to evaluate fibrosis (Goldner’s Trichrome) and
monocyte infiltration (CD11b staining). a, b Quantification (a) and representative images (b) (Trichrome 150×) of skin fibrosis in control (n = 5) and
AZA-treated (n = 7) mice. Ratios were calculated by dividing total thickness (TT, from epidermis to sub-cutaneous muscle layer) by collagen
thickness (CT, stained by Goldner’s Trichrome). c, d Ashcroft [36] quantification (c) and representative images (d) (Trichrome 100×) of lung fibrosis
in control (n = 4) and AZA-treated (n = 7) mice. e, f Quantification (e) and representative images (f) (IHC 100×) of monocyte infiltration in the skin
of control (n = 5) and AZA-treated (n = 8) mice. Results are expressed as median, 25th and 75th percentiles of the distribution (boxes), and whiskers
extending to the 5th and 95th percentiles. *P < 0.05
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that Hpall is not able to cut methylated sequences. As
expected, no differences were observed between groups
after Mspl digestion, while Hpall digestion demon-
strated reduced methylation levels of the Foxp3 enhan-
cer in Tregs in comparison with CD4+Tconvs, in
agreement with studies previously published by others
[29, 39] (Fig. 4d). We then assessed the methylation
status of the Foxp3 enhancer in total spleen cells col-
lected in cGVHD mice at the end of the experiment
(on day +52 after transplantation). As hypothesized, we
observed significantly less methylation of the Foxp3 enhan-
cer in AZA-treated mice (Fig. 4e). Similar findings were
made in DAC-treated mice (Additional File 1: figure S3).
Since the mTOR pathway is constitutively inactivated
in Tregs, they rely mainly on the STAT5 pathway for IL-2
signaling [37, 43]. In order to further investigate the im-
pact of AZA on day 30 after transplantation, we studied a
fifth cohort of mice given or not AZA 0.5 or 2 mg/kg
every other day from day +10 to day +30. In that cohort,
mice were sacrificed on day +30 after transplantation. We
observed that Tregs recovered from the spleen of mice
treated with AZA 2 mg/kg had higher levels of phosphory-
lated STAT5 (pSTAT5) than Tregs from control mice
(Fig. 4f). Further, they had also higher Tregs versus Tconvs
ratio of STAT5 phosphorylation level than control animals
(Fig. 4g). This higher IL-2 signaling in Tregs from
AZA-treated mice than in those from control mice
prompted us to assess the methylation status of the IL-2
promoter in spleen cells from control and AZA-treated
mice on day +52 after transplantation. For this, DNA was
digested with 2 restriction enzymes, PleI and MlyI. Both
enzymes recognize same CG sequences but PleI is sen-
sitive to methylation and is not able to cut when these
sequences are methylated. No differences were observed
between groups after MlyI treatment used as control while
PleI digestion demonstrated reduced methylation levels
in AZA-treated compared to control mice (Fig. 4h), in
agreement with findings previously published by other
groups [44–46].
AZA increases Treg frequency in thymus on day +35
Given that the thymus is the site of natural Treg gener-
ation on the one hand, and that thymic defects have been
involved in the pathogenesis of cGVHD on the other hand
[47, 48], we compared the thymus of AZA-treated and
control mice on day +35 after transplantation in a last
experiment. We observed that AZA-treated mice had
less cellularity, higher percentages of double negative
Fig. 3 Impact of azacytidine on blood cell counts and immune recovery. Balb/cJ mice were injected i.v. with 10.106 bone marrow cells and 70.106
splenocytes from B10.D2 donor mice after lethal irradiation. Mice were then given (or not) azacytidine (AZA, 0.5 mg/kg or 2 mg/kg), administered
subcutaneously every 48 h from day +10 to day +30. a–c Impact of AZA on total white blood cell counts (a), total lymphocyte counts (b) and
hemoglobin levels (c). d–g FACS analyses performed on mice blood at various time points showing lower counts and proliferation of CD4+Tconvs
(d, f) and of CD8+ T cells (e, g) during AZA administration but higher CD4+Tconvs (F) and of CD8+ T cells proliferation after AZA discontinuation.
Results are expressed as median, 25th and 75th percentiles of the distribution (boxes), and whiskers extending to the 5th and 95th percentiles.
*P < 0.05; **P < 0.01; ***P < 0.001
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thymocytes, and a trend for lower percentages of double
positive lymphocytes (Fig. 5a). Interestingly, there was a
significantly higher proportion of Tregs (defined as
CD90.2+CD4+CD8-Foxp3+) in the thymus of AZA-treated
mice than in those from control mice (Fig. 5b and c).
However, the proportion of Foxp3 double positive thymo-
cytes was very low and similar in both groups of mice
(data not shown), suggesting that the higher Treg fre-
quency observed in the thymus of AZA-treated mice was
due to higher Treg thymic recirculation. Finally, although
adequate cortico-medullar differentiation was conserved
in both control and AZA-treated mice, thymus from
AZA-treated mice tended to have smaller sizes (Fig. 5d),
in agreement with their lower cellularity (Fig. 5c).
AZA does not restrict T-cell receptor Vβ (TCRVβ)
repertoire
Given the anti-proliferative impact of AZA on T cells,
we compared the diversity of the TCRVβ repertoire on
days +35 and +52 after transplantation. As shown in
Additional File 1: figure S6, AZA did not significantly
impact TCRVβ repertoire diversity.
Discussion
Previous studies have demonstrated that HMA induced
the generation of Tregs in vitro, and prevented acute
GVHD in mouse-to-mouse models of transplantation
[30, 31]. Given the important divergences in the
pathogenesis of acute and chronic GVHD, we sought
to investigate the impact of AZA in a well-established
CD4-dependent murine model of scl-cGVHD. We se-
lected the dose and schedule of AZA administration based
on previous publications in mouse-to-mouse models of
acute GVHD [30, 31], and on prior observations by our
group in a humanized mouse model of GVHD [49]. The
dose of 2 mg/kg is close to the dose used in patients with
acute myeloid leukemia (75 mg/m2) [50, 51]. Several
observations were made.
First and most importantly, AZA indeed mitigated
cGVHD. This achievement was dependent on the sched-
ule of AZA administration since injection of AZA 2 mg/
kg every 2 days but not every 4 days was able to decrease
cGVHD severity. The ability of AZA to prevent cGVHD
in our mouse model is in line with the low incidence of
cGVHD observed in patients receiving donor lymphocytes
Fig. 4 Azacytidine increases Treg frequency and induces demethylation of Foxp3 enhancer and IL-2 promoter. Balb/cJ mice were injected i.v. with
10.106 bone marrow cells and 70.106 splenocytes from B10.D2 donor mice after lethal irradiation. Mice were then given (or not) azacytidine (AZA,
0.5 mg/kg or 2 mg/kg) administered subcutaneously every 48 h from day +10 to day +30. a, b FACS analyses showing the Tregs frequency in
two cohorts of mice combined (a) and in a third cohort of mice (b). c FACS analysis of activated CD103+ cells among Tregs in the spleens of
AZA on day +52 (data from the third cohort). d, e Methylation status of the Foxp3 enhancer assessed by methylation-sensitive restriction enzyme and
qPCR performed on genomic DNA of Tregs (n = 3) and Tconvs (n = 9) sorted from the spleen of three unmanipulated B10.D2 mice (d) or of the spleens
of control (n = 4) or AZA-treated (n = 5) recipient Balb/cJ mice at day +52 post transplantation (e). f FACS comparison of phosphorylated-STAT5 mean
fluorescence intensity (MFI) between Tregs in spleen of control (n = 8) and AZA-treated (n = 9) mice. g Comparison of ratio, for each mouse treated or
not with AZA, of pSTAT5 MFI of Tregs versus pSTAT5 MFI of Tconvs. h Methylation status of the IL-2 promoter assessed by MSRE-qPCR performed on
genomic DNA of spleens from control (n = 4) and AZA-treated (n = 5) recipient Balb/cJ mice at day +52 post transplantation. Results are expressed as
median, 25th and 75th percentiles of the distribution (boxes), and whiskers extending to the 5th and 95th percentiles. *P < 0.05; **P < 0.01
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infusion and AZA as treatment of acute myeloid leukemia
relapse after allo-HCT [52], and consistent with the very
low incidence of extensive cGVHD observed in patients
given prophylactic AZA after allo-HCT [53, 54], although
the latter patients also received alemtuzumab in the
conditioning regimen (which is associated with a very
low incidence of cGVHD by itself [55]).
At least two mechanisms were involved in cGVHD
prevention by AZA. First, AZA had an antiproliferative
effect on Tconvs during treatment. This is in line with
previous reports that demonstrated an anti T-cell prolif-
erative impact of HMA in vitro [30, 31]. Secondly, mice
given AZA had significantly higher Treg frequencies on
day 35 after transplantation, while a higher frequency of
Tregs had an activated (CD103+) phenotype on day +52
after transplantation. These observations are particularly
relevant given that a prior study had observed that in
vivo-activated CD103+ donor Tregs were much more ef-
ficient than resting donor Tregs at ameliorating ongoing
cGVHD [26]. These results are in concordance with the
Fig. 5 Azacytidine increases Treg frequency in the thymus on day +35. Balb/cJ mice were injected i.v. with 10.106 bone marrow cells and 70.106
splenocytes from B10.D2 donor mice after lethal irradiation. Mice were then given (or not) azacytidine (AZA, 2 mg/kg) administered subcutaneously
every 48 h from day +10 to day +30. On day +35, thymus from control (n = 6) and AZA-treated mice (n = 6) were collected. a, b FACS analyses showing
the frequencies of double negative CD4/CD8 cells (DN), double-positive CD4/CD8 cells (DP), single-positive CD4 cells (CD4 SP), and single-positive CD8
cells (CD8 SP) populations in the thymus (a) and the frequency of regulatory T cells among CD4 single-positive T cells (b). c Representative
graphs showing CD4+ T cells discriminated into conventional (CD4+Foxp3−) and regulatory T cells (CD4+Foxp3+) in control and AZA-treated
mice. d Histological evaluation (Hematoxylin-eosin, 100×) of thymic architecture in representative control and AZA-treated mice. Results are
expressed as median, 25th and 75th percentiles of the distribution (boxes), and whiskers extending to the 5th and 95th percentiles.
*P < 0.05; **P < 0.01
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higher Treg levels observed in patients given prophylac-
tic AZA after allo-HCT [54].
Interestingly, we also observed a higher frequency of
Tregs in the thymus of AZA-treated mice on day +35
after transplantation. Whether this was due to a higher
neogeneration of Tregs by the thymus or to a higher fre-
quency of peripheral Tregs recirculating into the thymus
remains to be determined in further experiment using
Rag2pGFP mice [56]. Indeed, we did not observe any in-
crease in the proportion of double positive thymocytes
expressing Foxp3 in the thymus of AZA-treated mice
compared to those of control animals.
It is likely that the higher Treg frequency observed in
AZA-treated mice on day +35 is the result of demethyla-
tion of several genes. This assumption is supported by the
demonstration of lower methylation status of both the
Foxp3 enhancer and the IL-2 promoter in the spleens from
AZA-treated mice in our study. Demethylation of the IL-2
promoter is particularly relevant, given the primordial role
of IL-2 in Treg homeostasis [20]. In line with the demeth-
ylation status of the IL-2 promoter in AZA-treated mice,
we observed higher pSTAT5 levels in Tregs from
AZA-treated than from control mice on day +30 after
transplantation, confirming that IL-2 signaling in
Tregs was higher in AZA-treated than in control mice.
Finally, as expected, AZA decreased blood counts and
delayed immune recovery. However, this negative impact
of the drug was rapidly corrected after AZA discontinu-
ation. Further, interestingly, AZA did not significantly
reduce the diversity of the TCRVβ repertoire.
Conclusions
In summary, our results indicate that AZA prevented
scl-cGVHD in a well-established murine model of cGVHD.
This was correlated with the demonstration of anti-
proliferative effects of AZA on T cells, as well as with a
higher frequency of Tregs (and particularly of activated
CD103+ Tregs) in mice receiving AZA. These observations
might serve as basis for pilot studies of AZA administration
for cGVHD prevention in patients at high risks for cGVHD
or for treatment of steroid-refractory scl-cGVHD.
Abbreviations
allo-HCT, allogeneic hematopoietic cell transplantation; AZA, azacytidine;
cGVHD, chronic graft-versus-host disease; DAC, decitabine; Foxp3, forkhead box
protein 3 factor; HMA, hypomethylating agents; Scl-cGVHD, sclerodermatous
cGVHD; Tconvs, conventional CD4+ T cells; TCRVβ, T-cell receptor Vβ;
Tregs, regulatory T cells
Additional file
Additional file 1: Figure S1. A): Azacytidine administered every fourth
day failed to prevent cGVHD. (B) Decitabine administered every other day
ameliorated cGVHD. Figure S2: Impact of Azacytidine on blood counts
and immune recovery after syngeneic transplantation. Figure S3: Impact of
decitabine on skin, lungs and immune recovery. Figure S4: Azacytidine
enhances Treg frequency and functions after syngeneic transplantation.
Figure S5: Azacytidine does not induce the generation of CD8+FoxP3+
regulatory T cells after allogeneic or syngeneic transplantation. Figure S6:
Azacytidine does not restrict T-cell Vβ (TCR Vβ) repertoire diversity on
day +35 and +52. (DOCX 10679 kb)
Acknowledgements
We are very grateful to Sandra Ormenese and Raafat Stephan from the
Imaging and Flow Cytometry Platform of the GIGA, to the ImmunoHistology
platform of the GIGA for histologic slides and the Genotranscriptomic
platform of the GIGA for TCRVβ analyses. The authors are also grateful to
Coline Daulne for excellent technical assistance.
Funding
This study was supported by funds from: the National Fund for Scientific
Research (FNRS), the Leon Fredericq fund and Anti-Cancer Center at the
University of Liège, and the Belgian Foundation Against Cancer. GF, GE, JM,
and LD are Télévie Research Assistant, JS a Televie postdoctoral researcher, and
FB is senior research associate of the National Fund for Scientific Research
(FNRS) Belgium. SHB is a postdoctoral researcher from the Fonds Wetenschap-
pelijk Onderzoek—Vlaanderen.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
this article and its additional files. Raw data are available on the GIGA extern
mass storage and access can be provided upon request to the authors.
Authors’ contribution
FB, GE, and SHB contributed to the design of the study. GF, GE, GC, and
FB conducted the data analyses. JC and YB helped with the study design
and data analyses. GF, GE, SD, LD, MH, and PD conducted mouse
experiments. GF and GE conducted the flow cytometry analyses. JS, PD,
and GF were in charge of histology. GC was in charge of PCR for
methylation status of Foxp3 enhancer and IL-2 promoter. FB, GF, GE, and
SHB were in charge of Ms writing. All authors read and approved the final
manuscript.
Competing interests
FB has received travel grants from Celgene.
Author details
1Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA)-I3,
Laboratory of Hematology, University of Liège, Liège, Belgium. 2GIGA-R,
Department of Pathology, University of Liège, Liège, Belgium. 3GIGA-R,
Animal care unit, University of Liège, Liège, Belgium. 4Department of
Medicine, Division of Hematology, CHU of Liège, Liège, Belgium.
5Translational Immunology Laboratory, VIB, Leuven, Belgium. 6Department of
Microbiology and Immunology, KU Leuven-University of Leuven, Leuven,
Belgium. 7Department of Hematology, University of Liège, CHU Sart-Tilman,
4000 Liège, Belgium.
Received: 1 April 2016 Accepted: 21 June 2016
References
1. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C,
Vindelov LL, Blaise D, Janssen JJ, Petersen E, et al. Impact of graft-versus-
host disease after reduced-intensity conditioning allogeneic stem cell
transplantation for acute myeloid leukemia: a report from the Acute
Leukemia Working Party of the European group for blood and marrow
transplantation. Leukemia. 2012;26:2462–8.
2. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow
Transplant T: Antileukemic effect of chronic graft-versus-host disease.
Contribution to improved survival after allogeneic marrow transplantation.
N Engl J Med. 1981;304:1529–33.
3. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE,
Chauncey TR, Flowers MED, Mielcarek M, et al. Graft-versus-tumor effects after
allogeneic hematopoietic cell transplantation with nonmyeloablative
conditioning. J Clin Oncol. 2005;23:1993–2003.
Fransolet et al. Journal of Hematology & Oncology  (2016) 9:53 Page 10 of 12
4. Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud
P, Petropoulou AD, Porcher R, Socie G. The graft-versus-leukemia effect is
mainly restricted to NIH-defined chronic graft-versus-host disease after
reduced intensity conditioning before allogeneic stem cell transplantation.
Leukemia. 2010;24:1852–8.
5. Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P,
Li QC, Zhang ZM, et al. Multicenter phase II study of a combination of
cyclosporine a, methotrexate and mycophenolate mofetil for GVHD
prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative
Group (CBMTCG). J Hematol Oncol. 2014;7:59.
6. Baron F, Zachee P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P,
Van Gelder M, Theunissen K, et al. Non-myeloablative allogeneic
hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or
ATG plus 8 Gy TLI: a phase II randomized study from the Belgian
Hematological Society. J Hematol Oncol. 2015;8:4.
7. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D,
Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socie G. Long-term survival
and late deaths after allogeneic hematopoietic cell transplantation. J Clin
Oncol. 2011;29:2230–9.
8. Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo
FM, Colado E, Martin J, Vazquez L, del Canizo C, et al. Prognostic factors of
chronic graft-versus-host disease following allogeneic peripheral blood stem
cell transplantation: the national institutes health scale plus the type of onset
can predict survival rates and the duration of immunosuppressive therapy. Biol
Blood Marrow Transplant. 2008;14:1163–71.
9. Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, Bacigalupo A,
Rambaldi A, Bonifazi F, Bosi A, et al. Unrelated cord blood transplantation
for adult patients with acute myeloid leukemia: higher incidence of acute
graft-versus-host disease and lower survival in male patients transplanted
with female unrelated cord blood-a report from Eurocord, the Acute
Leukemia Working Party, and the Cord Blood Committee of the Cellular
Therapy and Immunobiology Working Party of the European Group for
Blood and Marrow Transplantation. J Hematol Oncol. 2015;8:107.
10. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood.
2014;124:374–84.
11. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease
biology and therapy. Nat Rev Immunol. 2012;12:443–58.
12. de Masson A, Bouaziz JD, Le Buanec H, Robin M, O’Meara A, Parquet N,
Rybojad M, Hau E, Monfort JB, Branchtein M, et al. CD24(hi)CD27(+) and
plasmablast-like regulatory B cells in human chronic graft-versus-host
disease. Blood. 2015;125:1830–9.
13. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler
C, Ho VT, Alyea EP, Antin JH, et al. Altered regulatory T cell homeostasis in
patients with CD4+ lymphopenia following allogeneic hematopoietic stem
cell transplantation. J Clin Invest. 2010;120:1479–93.
14. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM,
Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, et al. Comparative
outcomes of donor graft CD34+ selection and immune suppressive therapy
as graft-versus-host disease prophylaxis for patients with acute myeloid
leukemia in complete remission undergoing HLA-matched sibling allogeneic
hematopoietic cell transplantation. J Clin Oncol. 2012;30:3194–201.
15. Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J, de la
Rubia J, Bargay J, Caballero D, Diez-Martin JL, et al. Allogeneic transplantation
of CD34 + -selected cells from peripheral blood in patients with myeloid
malignancies in early phase: a case control comparison with unmodified
peripheral blood transplantation. Bone Marrow Transplant. 2001;28:349–54.
16. Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L,
Ruutu T, Heim DA, Schwerdtfeger R, et al. Chronic graft-versus-host disease:
long-term results from a randomized trial on graft-versus-host disease
prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood.
2011;117:6375–82.
17. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R,
Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, et al.
Nonmyeloablative transplantation with or without alemtuzumab:
comparison between 2 prospective studies in patients with
lymphoproliferative disorders. Blood. 2002;100:3121–7.
18. Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A,
Selleri C, Risitano A, Messina G, et al. Antilymphocyte globulin for prevention of
chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.
19. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of
differentiation and function. Annu Rev Immunol. 2012;30:531–64.
20. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat
Rev Immunol. 2014;14:154–65.
21. Humblet-Baron S, Franckaert D, Dooley J, Bornschein S, Cauwe B,
Schonefeldt S, Bossuyt X, Matthys P, Baron F, Wouters C, Liston A. IL-2
consumption by highly activated CD8 T cells induces regulatory T-cell
dysfunction in patients with hemophagocytic lymphohistiocytosis. J Allergy
Clin Immunol. 2016. doi:10.1016/j.jaci.2015.12.1314. [Epub ahead of print].
22. Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C,
Koreth J, Alyea EP, Antin JH, et al. Low telomerase activity in CD4+
regulatory T cells in patients with severe chronic GVHD after hematopoietic
stem cell transplantation. Blood. 2011;118:5021–30.
23. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase
K, Cutler C, Ho VT, Alyea EP, et al. Low-dose interleukin-2 therapy restores
regulatory T cell homeostasis in patients with chronic graft-versus-host
disease. Sci Transl Med. 2013;5:179ra143.
24. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, Strober S, Zeng D.
Donor CD4+ T and B cells in transplants induce chronic graft-versus-host
disease with autoimmune manifestations. Blood. 2006;107:2993–3001.
25. Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier
JF, Moreau P, Gregoire M, Gaugler B, Mohty M. Increased Th17/Treg ratio in
chronic liver GVHD. Bone Marrow Transplant. 2014;49:539–44.
26. Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. In
vivo-activated CD103 + CD4+ regulatory T cells ameliorate ongoing chronic
graft-versus-host disease. Blood. 2008;112:2129–38.
27. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development
and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.
28. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of
regulatory T cells. Immunity. 2013;38:414–23.
29. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy
DE, Bromberg JS. Epigenetic regulation of Foxp3 expression in regulatory T
cells by DNA methylation. J Immunol. 2009;182:259–73.
30. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T,
Blanco B, Herrero-Sanchez C, Garcia JL, Carrancio S, Hernandez-Campo P,
Gonzalez FJ, et al. Immunomodulatory effect of 5-azacytidine (5-azaC):
potential role in the transplantation setting. Blood. 2010;115:107–21.
31. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms
DR, DiPersio JF. In vivo administration of hypomethylating agents mitigate
graft-versus-host disease without sacrificing graft-versus-leukemia. Blood.
2010;116:129–39.
32. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a
model for scleroderma. I. Description of model systems. Cell Immunol.
1983;77:1–12.
33. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease:
insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14:
365–78.
34. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease:
advances and limitations. Dis Model Mech. 2011;4:318–33.
35. Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R,
Drion P, Zilberberg J, Bogen B, et al. Establishment of a murine graft-
versus-myeloma model using allogeneic stem cell transplantation. PLoS
One. 2014;9:e113764.
36. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of
pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467–70.
37. Ehx G, Hannon M, Beguin Y, Humblet-Baron S, Baron F. Validation of a
multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell
subsets. Oncotarget. 2015;6:43255–66.
38. Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T,
Daulne C, de Bock M, et al. Immune recovery after allogeneic
hematopoietic stem cell transplantation following Flu-TBI versus TLI-ATG
conditioning. Clin Cancer Res. 2015;21:3131–9.
39. Oakes CC, La Salle S, Trasler JM, Robaire B. Restriction digestion and real-
time PCR (qAMP). Methods Mol Biol. 2009;507:271–80.
40. Novak TJ, White PM, Rothenberg EV. Regulatory anatomy of the murine
interleukin-2 gene. Nucleic Acids Res. 1990;18:4523–33.
41. Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, Varelias A,
Alexander KA, Teal BE, Sparwasser T, et al. Identification and expansion of
highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental
allogeneic bone marrow transplantation. Blood. 2012;119:5898–908.
42. Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR.
CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host
disease and mitigate disease severity. J Immunol. 2012;189:464–74.
Fransolet et al. Journal of Hematology & Oncology  (2016) 9:53 Page 11 of 12
43. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J,
Hou JZ, Negrin RS. Differential impact of mammalian target of rapamycin
inhibition on CD4 + CD25 + Foxp3+ regulatory T cells compared with
conventional CD4+ T cells. Blood. 2008;111:453–62.
44. Ballas ZK. The use of 5-azacytidine to establish constitutive interleukin 2-
producing clones of the EL4 thymoma. J Immunol. 1984;133:7–9.
45. Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y,
Wang Y, Ushijima T, Baba T, Shibuya K, et al. A specific CpG site
demethylation in the human interleukin 2 gene promoter is an epigenetic
memory. EMBO J. 2006;25:1081–92.
46. Bruniquel D, Schwartz RH. Selective, stable demethylation of the
interleukin-2 gene enhances transcription by an active process. Nat
Immunol. 2003;4:235–40.
47. Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R,
Willems E, Gothot A, Vanbellinghen JF, Geenen V, et al. Thymic recovery
after allogeneic hematopoietic cell transplantation with non-myeloablative
conditioning is limited to patients younger than 60 years of age.
Haematologica. 2011;96:298–306.
48. Wu T, Young JS, Johnston H, Ni X, Deng R, Racine J, Wang M, Wang A,
Todorov I, Wang J, Zeng D. Thymic damage, impaired negative selection,
and development of chronic graft-versus-host disease caused by donor
CD4+ and CD8+ T cells. J Immunol. 2013;191:488–99.
49. Ehx G, Fransolet G, De Leval L, D’Hondt S, Lucas S, Hannon M, Delens L,
Dubois S, Drion P, Beguin Y, et al. Azacytidine enhances regulatory T-cells in
vivo and prevents experimental xenogeneic graft-versus-host disease. Biol
Blood Marrow Transplant. 2016;22:s393–3.
50. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J,
Halter B, Machherndl-Spandl S, Zebisch A, et al. Azacitidine front-line in 339
patients with myelodysplastic syndromes and acute myeloid leukaemia:
comparison of French-American-British and World Health Organization
classifications. J Hematol Oncol. 2016;9:39.
51. van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den
Berg E, Vellenga E, Huls G. Azacitidine might be beneficial in a subgroup of
older AML patients compared to intensive chemotherapy: a single centre
retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.
52. Steinmann J, Bertz H, Wasch R, Marks R, Zeiser R, Bogatyreva L, Finke J,
Lubbert M. 5-Azacytidine and DLI can induce long-term remissions in AML
patients relapsed after allograft. Bone Marrow Transplant. 2015;50:690–5.
53. Craddock C, Jilani NY, Siddique S, Yap C, Khan JN, Nagra S, Ward J,
Ferguson P, Hazlewood P, Buka R, et al. Tolerability and clinical activity of
post-transplantation azacitidine in patients allografted for acute myeloid
leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2015.
54. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J,
Khanum R, Raghavan M, Cook M, et al. Azacitidine augments expansion of
regulatory T cells after allogeneic stem cell transplantation in patients with
acute myeloid leukemia (AML). Blood. 2012;119:3361–9.
55. Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal
M, Jindra P, Goker H, Socie G, et al. Impact of in vivo T-cell depletion on
outcome of AML patients in first CR given peripheral blood stem cells and
reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor:
a report from the Acute Leukemia Working Party of the European Group for
Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389–96.
56. Yu W, Nagaoka H, Jankovic M, Misulovin Z, Suh H, Rolink A, Melchers F,
Meffre E, Nussenzweig MC. Continued RAG expression in late stages of B
cell development and no apparent re-induction after immunization. Nature.
1999;400:682–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fransolet et al. Journal of Hematology & Oncology  (2016) 9:53 Page 12 of 12
